JIC
CATX icon

Joel Isaacson & Co’s Perspective Therapeutics CATX Stock Holding History

Joel Isaacson & Co’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-500
Closed -$7K – 750
2015
Q3 		$7K Hold
500
– – ﹤0.01% 603
2015
Q2 		$7K Hold
500
– – ﹤0.01% 628
2015
Q1 		$8K Buy
+500
New +$7.42K ﹤0.01% 585

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Joel Isaacson & Co's CATX Position: Q4 2015 in Review

Joel Isaacson & Co sold out of Perspective Therapeutics (CATX) in Q4 2015, closing a stake of 500 shares — an estimated $7K sold.

Joel Isaacson & Co first reported a position in CATX in Q1 2015 and held it in 3 quarters. The position peaked at $8K in Q1 2015. 26 funds tracked by Wall St. Rank hold CATX as of Q4 2015.

  • Joel Isaacson & Co reported no remaining Perspective Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Joel Isaacson & Co sold 500 Perspective Therapeutics shares in Q4 2015, an estimated $7K.
  • Joel Isaacson & Co first reported a position in Perspective Therapeutics in Q1 2015 and held it in 3 quarters.
  • Joel Isaacson & Co's Perspective Therapeutics position peaked at $8K in Q1 2015.
  • 26 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2015.

Based on Joel Isaacson & Co's 13F filing for Q4 2015, filed 15 Jan 2016.